Letrozole: an emerging array of hope for infertile women


  • Manish Maladkar Department of Scientific, Medical and Regulatory Affairs, Aristo Pharmaceuticals Private Limited, Mumbai, Maharashtra, India
  • Chitra Tekchandani Department of Scientific, Medical, Aristo Pharmaceuticals Private Limited, Mumbai, Maharashtra, India
  • Akshata Karchodi Department of Scientific, Aristo Pharmaceuticals Private Limited, Mumbai, Maharashtra, India




Anti-estrogenic effects, Anovulation, Aromatase inhibitors, Clomiphene citrate resistance, Infertility, Oral ovulation inducers, Polycystic ovary syndrome, Unexplained infertility


Ovulation induction has been a major breakthrough in the management of female infertility since many decades. Letrozole, an aromatase inhibitor has been used as a potential therapy for ovulation induction. A large number of clinical evidences have been emerging which cite the beneficial role of Letrozole in conditions like anovulatory infertility, polycystic ovary syndrome (PCOS), unexplained infertility and an incipient role in endometriosis- related infertility with regards to higher live-birth rates. Letrozole is a superior alternative to Clomiphene citrate (CC) which has been used conventionally as ovulation inducer. Clomiphene citrate has certain well-defined disadvantages, whereas Letrozole overcomes these limitations to a reasonable extent. The peripheral anti-estrogenic effect of CC leads to prolonged depletion of estrogens receptors, adversely affecting endometrial growth and development as well as quantity and quality of cervical mucus. Persistent blockade of estrogen receptor leads to CC resistance and is associated with reduced ovulation and pregnancy rates. Available evidences suggest Letrozole is superior to CC owing to the lack of persistent anti-estrogenic action due to its short half- life and lack of action on estrogen receptors. This typically leads to monofollicular growth and also higher live birth rates. The current evidences suggest that Letrozole can be placed as first line therapy for the management of infertility due to PCOS and unexplained infertility.


Norwitz E, Schust DJ, Fisher SJ. Implantation and the survival of early pregnancy. N Engl J Med. 2001;345:1400-8.

Gurunath S, Pandian Z, Anderson RA, Bhattacharya S. Defining infertility-a systematic review of prevalence studies. Human Repro Update. 2011;17(5):575-88.

Practice Committee of American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2012;98(2):302-7.

Singh K, Kumari R, Ranjan R, Bharti G. Analysis of causes and clinical pattern of infertility in couples coming to a tertiary care centre in Bihar, India. Int J Reprod Contracept Obstet Gynecol. 2017;6(6):2279-83.

Mittal S. Investigating infertility. In: Gutgutia R Infertility management series. 1st edition. Jaypee Brothers Med Publishers (P) Ltd; 2018:356-357.

Mascarenhas MN, Cheung H, Mathers CD, Stevens GA. Measuring infertility in populations: constructing a standard definition for use with demographic and reproductive health surveys. Population Health Metrics. 2012;10:17.

Gokler ME, Unsal A, Arslantas D. The prevalence of infertility and loneliness among women aged 18-49 years who are living in semi-rural areas in Western Turkey. Int J Fertil Steril. 2014;155-162.

Sharma KS, Biedenharn KR, Fedor J, Agarwal A. Lifestyle factors and reproductive health: Taking control of your fertility. Repro Biol Endocrinol. 2013;11(1):66.

Bhattacharya S, Johnson N, Tijani HA, Hart R, Pandey S, Gibreel AF. Female infertility. BMJ Clin Evid. 2010;2010:0819.

Lin PC, Bhatnagar KP, Stephen N, Nakajima TN. Female genital anomalies affecting reproduction. Fertil Steril. 2002;78:899-915.

Katsikis I, Kita M, Karkanaki A, Prapas N, Panidis D. Anovulation and ovulation induction. Hippokratia. 2006;10(3):120-7.

Homburg R. Clomiphene citrate-end of an era? a mini-review. Human Repro. 2005;20(8):2043-51.

Snegovskikh VV. Clomiphene citrate (CC) administration changes cervical mucus permeability in patients undergoing fertility treatments. Fert Steril. 2014;102(3):e306.

Wada M, Kasai T, Nagai S, Fujie M, Miyake M, Suzuk K, et al. Effect of repeated administration of clomiphene citrate at two different times on the endometrium in patients undergoing intrauterine insemination. Repro Med Biol. 2004;3:153-7.

Omran E, Sharkawy ME, Mazny AE, Hammam M, Ramadan W, Latif D, et al. Effect of clomiphene citrate on uterine hemodynamics in women with unexplained infertility. Int J Womens Health. 2018;10:147-52.

Ergur AR, Yergok YZ, Ertekin A, Kuçuk T, Mungen E, Tutuncu L. Clomiphene citrate-resistant polycystic ovary syndrome. Preventing multifollicular development. J Reprod Med. 1998;43(3):185-90.

Saha L, Kaur S, Saha PK. N-acetyl cysteine in clomiphene citrate resistant polycystic ovary syndrome: a review of reported outcomes. J Pharmacol Pharmacother. 2013;4(3):187-91.

Kamath MS, George K. Letrozole or clomiphene citrate as first line for anovulatory infertility: a debate. Repro Biol Endocrinol. 2011;9:86.

Karaer O, Oruc S, Koyuncu FM. Aromatase inhibitors: possible future applications. Acta Obstet Gynecol Scand. 2004;83:699-706.

Casper RF, Mitwally MF. A historical perspective of aromatase inhibitors for ovulation induction. Fertil Steril. 2012;98(6):1352-5.

Takasaki A, Tamura H, Taketani T, Shimamura K, Morioka H, Sugino N. A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment. J Ovarian Res. 2013;6(1):94.

Mitwally MFM, Casper RF. Aromatase Inhibitors in Ovulation Induction. Semin Reprod Med. 2004;22(1):61-78.

Kar S. Current evidence supporting “letrozole” for ovulation induction. J Hum Reprod Sci. 2013;6(2):93-8.

Pritts EA, Yuen AK, Sharma S, Genisot R, Olive DL. The use of high dose letrozole in ovulation induction and controlled ovarian hyperstimulation. ISRN Obstet Gynecol. 2011;2011:242864.

Wang L, Wen X, Lv S, Zhao J, Yang T, Yang. Comparison of endometrial receptivity of clomiphene citrate versus letrozole in women with polycystic ovary syndrome: a randomized controlled study. Gynecol Endocrinol. 2019;12:1-4.

Radjenovic SS, Peulic LS, Gudovic A, Vidakovic S, Bila J. Letrozole versus clomiphene as the first-line treatment for anovulatory infertility in women with PCOS, 2018. Available at: https://isge2018.isgesociety.com/wp-content/app/abs/pdf/abs7373.pdf. Accessed on 6th June 2019.

Chakravorty R, Athwal A, Sur D, Saha R. A prospective, randomized trial comparing the effects of letrozole versus clomiphene citrate for induction of ovulation and pregnancy rate in women with polycystic ovary syndrome. Fertil Sci Res. 2016;3:93-7.

Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. N Engl J Med. 2014;371:119-29.

Roy KK, Baruah J, Singla S, Sharma JB, Singh N, Jain SK, et al. A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. J Hum Reprod Sci. 2012;5(1):20-5.

Harira M. Use of Letrozole versus clomiphene-estradiol for treating infertile women with unexplained infertility not responding well to clomiphene alone, comparative study. Middle East Fertility Society J. 2018;23(4):384-8.

Fouda UM, Sayed AM. Extended letrozole regimen versus clomiphene citrate for superovulation in patients with unexplained infertility undergoing intrauterine insemination: a randomized controlled trial. Reprod Biol Endocrinol. 2011;9:84.

Barroso G, Menocal G, Felix H, Rojas-Ruiz JC, Arslan M, Oehninger S. Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphene citrate as adjuvants to recombinant follicle-stimulating hormone in controlled ovarian hyperstimulation: a prospective, randomized, blinded clinical trial. Fertil Steril. 2006;86(5):1428-31.

Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75:305-9.

Ibrahim MH, Tawfic M, Hassan MM, Sedky OH. Letrozole versus laparoscopic ovarian drilling in infertile women with PCOS resistant to clomiphene citrate. Middle East Fertil Soc J. 2017:1-4.

EL-Gharib MN, Mahfouz AE, Farahat MA. Comparison of Letrozole versus Tamoxifen effects in Clomiphen citrate resistant women with polycystic ovarian syndrome. J Reprod Infertil. 2015;16(1):30-5.

Rahmani E, Ahmadi S, Motamed N, Maneshi HO. Dosage optimization for Letrozole treatment in Clomiphene-resistant patients with polycystic ovary syndrome: a prospective interventional study. Obstet Gynecol Int. 2012;2012:758508.

Elnashar A, Fouad H, Eldosoky M, Saeid N. Letrozole induction of ovulation in women with clomiphene citrate-resistant polycystic ovary syndrome may not depend on the period of infertility, the body mass index, or the luteinizing hormone/follicle-stimulating hormone ratio. Fertil Steril. 2006;85(2):511-3.

Hashim HA. Aromatase inhibitors for endometriosis-associated infertility; do we have sufficient evidence? Int J Fertil Steril. 2016;10(3):270-7.

Sacco K, Portelli M, Pollacco J, Wismayer SP, Agius JC. The role of prostaglandin E2 in endometriosis. Gynecol Endocrinol. 2012;28(2):134-8.

Pavone ME, Bulun SE. Aromatase inhibitors for the treatment of endometriosis. Fertil Steril. 2012;98(6):1370-9.

Mitra PS, Sirazee HH, Latha B.V, Dasgupta M, Adhikari S. A prospective randomized comparative study of Letrozole versus Leuprolide acetate in symptomatic relief of endometriosis. Int J Pharma Sci Invent. 2013;2(6):32-8.

Kumar N, Singh AK. Trends of male factor infertility, an important cause of infertility: a review of literature. J Hum Reprod Sci. 2015;8(4):191-6.

de Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol. 2011;9:93.






Review Articles